跳至主要内容
临床试验/EUCTR2011-000842-39-IT
EUCTR2011-000842-39-IT进行中(未招募)不适用

A Comparison of LY2605541 versus Insulin Glargine as Basal Insulin Treatment in Combination with Oral Anti-Hyperglycemia Medications in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Study The IMAGINE 2 Study - IMAGINE 2

ELI LILLY0 个研究点目标入组 1,516 人开始时间: 2011年11月14日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
ELI LILLY
入组人数
1,516

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • T2DM (per World Health Organization [WHO] Classification of Diabetes not treated with insulin [2] Age 18 years of age or older [3] Duration of diabetes = 1 year
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 1137
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 379

排除标准

  • Insulin therapy: have used insulin therapy (outside of pregnancy) anytime in the past 2 years, except for short term treatment of acute conditions, and up to a maximum of 4 continuous weeks. [13] Concomitant medications: Rosiglitazone, glucagon-like peptide-1 (GLP-1) receptor agonist (for example, exenatide, exenatide onceweekly or liraglutide) used concurrently or within 3 months prior to screening. [14] Local OAM restrictions: for patients on OAMs, restrictions for cardiac, renal and hepatic diseases, local product regulations must apply [15] Prescription weight loss medications: are currently taking, or have taken within the 3 months preceding screening, prescription or over-thecounter medications to promote weight loss. [16] Severe hypoglycemia history

研究者

发起方
ELI LILLY

相似试验